Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results